Case number 2018-1804
Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | SANOFI-AVENTIS U.S., LLC v. FRESENIUS KABI USA, LLC [OPINION - PRECEDENTIAL] [precedential] (0) |
| Sep 20, 2019 | 127 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [636969] [18-1804, 18-1808, 18-1809] [JAB] [Entered: 09/20/2019 09:56 AM] (2) |
| Aug 28, 2019 | 126 | Bill of Costs for Appellants Sanofi, Sanofi Mature IP and Sanofi-Aventis U.S., LLC. Service: 08/28/2019 by email. [631779] [18-1804] [Katherine Adams] [Entered: 08/28/2019 06:22 PM] (0) |
| Aug 14, 2019 | 124 | OPINION filed for the court by Lourie, Circuit Judge; Moore, Circuit Judge and Taranto, Circuit Judge. Precedential Opinion. [628103] [18-1804, 18-1808, 18-1809] [JAB] [Entered: 08/14/2019 09:54 AM] (24) |
| Aug 14, 2019 | 125 | JUDGMENT. AFFIRMED-IN-PART AND VACATED-IN-PART. Terminated on the merits after oral argument. COSTS: Costs awarded to Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [628105] [18-1804, 18-1808, 18-1809] [JAB] [Entered: 08/14/2019 09:56 AM] (2) |
| Jun 5, 2019 | 123 | Submitted after ORAL ARGUMENT by Mr. William E. Solander for Sanofi-Aventis U.S., LLC, Sanofi and Sanofi Mature IP, Mr. Andrew M. Alul for Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited and Emily L. Rapalino for Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Panel: Judge: Lourie , Judge: Moore , Judge: Taranto. [611647] [JCP] [Entered: 06/05/2019 11:03 AM] (0) |
| May 16, 2019 | 121 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [120], ERROR: Counsel submitted a response to the notice of oral argument indicating half minutes of argument time. CORRECTION: Time can not be divided into half minutes. Please promptly submit a corrected response. [607780] [JAB] [Entered: 05/16/2019 08:00 AM] (0) |
| May 16, 2019 | 122 | AMENDED Response to notice of oral argument from the Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. [607946] [18-1804] [Andrew Alul] [Entered: 05/16/2019 02:18 PM] (4) |
| May 15, 2019 | 117 | Response to notice of oral argument from the Appellee Sandoz, Inc.. [607478] [18-1804] [Laura Lydigsen] [Entered: 05/15/2019 11:33 AM] (3) |
| May 15, 2019 | 118 | Response to notice of oral argument from the Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. [607485] [18-1804] [Frank Rodriguez] [Entered: 05/15/2019 11:50 AM] (3) |
| May 15, 2019 | 119 | Response to notice of oral argument from the Appellants Sanofi, Sanofi Mature IP and Sanofi-Aventis U.S., LLC. [607747] [18-1804] [William Solander] [Entered: 05/15/2019 06:56 PM] (3) |
| May 15, 2019 | 120 | Response to notice of oral argument from the Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. [607751] [18-1804] [Andrew Alul] [Entered: 05/15/2019 07:15 PM] (4) |
| Apr 22, 2019 | 116 | NOTICE OF ORAL ARGUMENT. Panel: 1906I. Case scheduled Jun 05, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to Notice of Oral Argument due: 05/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [601917] [JAB] [Entered: 04/22/2019 01:13 PM] (2) |
| Mar 8, 2019 | 115 | **TEXT ONLY** ORDER granting motion to withdraw attorney [114] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi and Sanofi Mature IP. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [591318] [TAM] [Entered: 03/08/2019 08:21 AM] (0) |
| Mar 7, 2019 | 114 | MOTION of Appellants Sanofi, Sanofi Mature IP and Sanofi-Aventis U.S., LLC to withdraw counsel Jason A. Leonard [Consent: unopposed]. Service: 03/07/2019 by email. [591187] [18-1804] [William Solander] [Entered: 03/07/2019 01:44 PM] (7) |
| Feb 7, 2019 | 110 | Notice from Appellants Sanofi, Sanofi Mature IP and Sanofi-Aventis U.S., LLC regarding conflicts with oral argument. None. Service: 02/07/2019 by email. [584050] [18-1804] [William Solander] [Entered: 02/07/2019 11:36 AM] (0) |
| Feb 7, 2019 | 111 | Notice from Cross-Appellants Apotex Corp. and Apotex Inc. regarding conflicts with oral argument. None. Service: 02/07/2019 by email. [584094] [18-1804] [Andrew Alul] [Entered: 02/07/2019 01:20 PM] (0) |
| Feb 7, 2019 | 112 | Notice from Cross-Appellants Actavis Elizabeth LLC, Actavis LLC and Fresenius Kabi USA, LLC regarding conflicts with oral argument. Service: 02/07/2019 by email. [584116] [18-1804] [Daryl Wiesen] [Entered: 02/07/2019 02:14 PM] (3) |
| Feb 7, 2019 | 113 | Notice from Cross-Appellant Mylan Laboratories Limited regarding conflicts with oral argument. None. Service: 02/07/2019 by email. [584128] [18-1804] [Matthew Reed] [Entered: 02/07/2019 02:37 PM] (0) |
| Feb 6, 2019 | 109 | 6 paper copies of the Confidential Joint Appendix Brief (Vol. I - IV) [93] received from Appellants Sanofi, Sanofi-Aventis U.S., LLC, Appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Sandoz, Inc. and Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. [583761] [CJF] [Entered: 02/06/2019 12:18 PM] (0) |
| Feb 4, 2019 | 108 | 6 paper copies of the Reply Brief [90] received from Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. [583015] [CJF] [Entered: 02/04/2019 09:55 AM] (0) |
| Jan 31, 2019 | 104 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [CLERK'S NOTE: Attorney Imron T. Aly, Helen H. Ji, and Roshan Shrestha's contact information listed on the briefs do not match the contact information on the accounts. Please update ECF account information at www.pacer.gov or file an amended EOA reflecting the correct information.] [582413] [TAM] [Entered: 01/31/2019 01:19 PM] (0) |
| Jan 31, 2019 | 105 | ORDER filed. The motion [97] is granted. The revised official caption is reflected in this order. A copy of this order shall be transmitted to the merits panel assigned to this appeal to inform the panel of the caption change.; - FOR CALENDAR. Service: 01/31/2019 by clerk. [582451] [LMS] [Entered: 01/31/2019 02:51 PM] (2) |
| Jan 31, 2019 | 106 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [582468] [TAM] [Entered: 01/31/2019 03:27 PM] (0) |
| Jan 31, 2019 | 107 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The notice of conflict with oral argument is due on or before 02/07/2019. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [582472] --[Edited 02/01/2019 by CAB to attach corrected Notice] [TAM] [Entered: 01/31/2019 03:29 PM] (1) |
| Jan 24, 2019 | 97 | MOTION of Sanofi Mature IP Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC to substitute party [Consent: unopposed]. Service: 01/24/2019 by email. [580607] [18-1804] [William Solander] [Entered: 01/24/2019 01:31 PM] (12) |
| Jan 24, 2019 | 98 | Amended Entry of appearance for William E. Solander as principal counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC Sanofi Mature IP. Service: 01/24/2019 by email. [580610] [18-1804] [William Solander] [Entered: 01/24/2019 01:34 PM] (2) |
| Jan 24, 2019 | 99 | Amended Entry of appearance for Dominick A. Conde as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC Sanofi Mature IP. Service: 01/24/2019 by email. [580615] [18-1804] [William Solander] [Entered: 01/24/2019 01:37 PM] (2) |
| Jan 24, 2019 | 100 | Amended Entry of appearance for Daniel J. Minion as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC Sanofi Mature IP. Service: 01/24/2019 by email. [580617] [18-1804] [William Solander] [Entered: 01/24/2019 01:39 PM] (2) |
| Jan 24, 2019 | 101 | Amended Entry of appearance for Jason A. Leonard as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC Sanofi Mature IP. Service: 01/24/2019 by email. [580620] [18-1804] [William Solander] [Entered: 01/24/2019 01:41 PM] (2) |
| Jan 24, 2019 | 102 | Amended Entry of appearance for Whitney L. Meier as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC Sanofi Mature IP. Service: 01/24/2019 by email. [580622] [18-1804] [William Solander] [Entered: 01/24/2019 01:43 PM] (2) |
| Jan 24, 2019 | 103 | Amended Entry of appearance for Katherine E. Adams as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC Sanofi Mature IP. Service: 01/24/2019 by email. [580624] [18-1804] [William Solander] [Entered: 01/24/2019 01:45 PM] (2) |
| Jan 9, 2019 | 96 | Amended Certificate of Interest for the Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/09/2019 by email. [577142] [18-1804] [Whitney Meier] [Entered: 01/09/2019 06:35 PM] (3) |
| Dec 10, 2018 | 91 | Joint Statement of Compliance with Fed. Cir. R. 33 for Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC, Mylan Laboratories Limited, Appellants Aventis Pharma S.A., Sanofi, Sanofi-Aventis U.S., LLC and Appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Sandoz, Inc.. Service: 12/10/2018 by email. [570688] [18-1804] [William Solander] [Entered: 12/10/2018 08:54 PM] (5) |
| Dec 10, 2018 | 92 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 12/10/2018 by email. [570689] [18-1804] [William Solander] [Entered: 12/10/2018 08:58 PM] (6) |
| Dec 10, 2018 | 93 | MODIFIED ENTRY: CONFIDENTIAL JOINT APPENDIX FILED for Aventis Pharma S.A., Sanofi, Sanofi-Aventis U.S., LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Sandoz, Inc. and Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Number of Pages: 1754. Service: 12/10/2018 by email. [570692]--[Edited 01/31/2019 by TAM - compliance review complete] [William Solander] [Entered: 12/10/2018 10:29 PM] (0) |
| Dec 10, 2018 | 94 | MODIFIED ENTRY: JOINT APPENDIX FILED for Aventis Pharma S.A., Sanofi, Sanofi-Aventis U.S., LLC, Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Sandoz, Inc. and Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Number of Pages: 1714. Service: 12/10/2018 by email. [570694] --[Edited 01/31/2019 by TAM - compliance review complete] [William Solander] [Entered: 12/10/2018 10:35 PM] (1714) |
| Dec 10, 2018 | 95 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 12/10/2018 by email. [570695] [18-1804] [Andrew Alul] [Entered: 12/10/2018 11:26 PM] (16) |
| Nov 28, 2018 | 90 | MODIFIED ENTRY: REPLY BRIEF FILED for Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Number of Pages: 32. Service: 11/28/2018 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [568285] --[compliance review complete - Edited 12/13/2018 by SMJ] [Daryl Wiesen] [Entered: 11/28/2018 03:33 PM] (55) |
| Nov 7, 2018 | 89 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [86], ERROR: Attorney Jason Leonard has not updated his information in CM/ECF. CORRECTION: Counsel should promptly update his information in CM/ECF to match the information on his amended entry of appearance. [563338] [MMA] [Entered: 11/07/2018 03:17 PM] (0) |
| Nov 6, 2018 | 83 | Amended Entry of appearance for William E. Solander as principal counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 11/06/2018 by email. [563098] [18-1804] [Katherine Adams] [Entered: 11/06/2018 05:48 PM] (2) |
| Nov 6, 2018 | 84 | Amended Entry of appearance for Daniel J. Minion as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 11/06/2018 by email. [563100] [18-1804] [Katherine Adams] [Entered: 11/06/2018 05:51 PM] (2) |
| Nov 6, 2018 | 85 | Amended Entry of appearance for Dominick A. Conde as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 11/06/2018 by email. [563101] [18-1804] [Katherine Adams] [Entered: 11/06/2018 05:53 PM] (2) |
| Nov 6, 2018 | 86 | Amended Entry of appearance for Jason A. Leonard as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 11/06/2018 by email. [563103] [18-1804] [Katherine Adams] [Entered: 11/06/2018 05:56 PM] (2) |
| Nov 6, 2018 | 87 | Amended Entry of appearance for Whitney L. Meier as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 11/06/2018 by email. [563104] [18-1804] [Katherine Adams] [Entered: 11/06/2018 05:57 PM] (2) |
| Nov 6, 2018 | 88 | Amended Entry of appearance for Katherine E. Adams as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 11/06/2018 by email. [563106] [18-1804] [Katherine Adams] [Entered: 11/06/2018 05:59 PM] (2) |
| Nov 1, 2018 | 82 | 6 paper copies of the Reply Brief [80] received from Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. [561923] [CJF] [Entered: 11/01/2018 01:28 PM] (0) |
| Oct 30, 2018 | 81 | **TEXT ONLY** ORDER granting motion to extend time to file brief [79] filed by Cross-Appellants Apotex Inc., Apotex Corp., Actavis Elizabeth LLC, Accord Healthcare, Inc., Actavis LLC, Mylan Laboratories Limited and Fresenius Kabi USA, LLC. Cross-Appellant's reply brief is due 11/28/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [561466] [JB] [Entered: 10/30/2018 04:52 PM] (0) |
| Oct 29, 2018 | 79 | MOTION of Cross-Appellants Actavis LLC, Actavis Elizabeth LLC, Fresenius Kabi USA, LLC, Accord Healthcare, Inc., Apotex Corp., Apotex Inc. and Mylan Laboratories Limited to extend the time to 11/28/2018 to file the Defendants-Cross-Appellants Reply Brief. [Consent: unopposed]. Service: 10/29/2018 by email. [561095] [18-1804] [Aviv Zalcenstein] [Entered: 10/29/2018 06:39 PM] (19) |
| Oct 24, 2018 | 78 | TENDERED from Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Title: REPLY BRIEF. Service: 10/24/2018 by email. [560225] [18-1804] [William Solander] [Entered: 10/24/2018 10:00 PM] (86) |
| Oct 24, 2018 | 80 | REPLY BRIEF FILED for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC [78]. Number of Pages: 68. Service: 10/24/2018 by email. The paper copies of the brief should be received by the court on or before 11/06/2018. Cross-Appellant's reply brief is due 11/07/2018. [561463] [JB] [Entered: 10/30/2018 04:47 PM] (86) |
| Oct 1, 2018 | 77 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [76] filed by Appellants Aventis Pharma S.A., Sanofi-Aventis U.S., LLC and Sanofi. Reply brief is due 10/24/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [553501] [SJ] [Entered: 10/01/2018 09:51 AM] (0) |
| Sep 27, 2018 | 76 | MOTION of Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC to extend the time to 10/24/2018 to file the Plaintiffs-Appellants' Response and Reply Brief. [Consent: unopposed]. Service: 09/27/2018 by email. [552928] [18-1804] [Whitney Meier] [Entered: 09/27/2018 09:53 AM] (8) |
| Sep 13, 2018 | 75 | 6 paper copies of the Partial Joinder Brief [74] received from Appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Sandoz, Inc.. [549500] [CJF] [Entered: 09/13/2018 01:09 PM] (0) |
| Aug 31, 2018 | 72 | TENDERED from Appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Sandoz, Inc.. Title: NOTICE OF JOINDER. Service: 08/31/2018 by email. [546780] [18-1804] [Laura Lydigsen] [Entered: 08/31/2018 04:03 PM] (8) |
| Aug 31, 2018 | 73 | 6 paper copies of the Principal and Opening Response Brief [71] received from Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. [546792] [CJF] [Entered: 08/31/2018 04:17 PM] (0) |
| Aug 31, 2018 | 74 | Notice of Joinder for Appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Sandoz, Inc. [72] joining in [71] Response Brief submitted by Cross-Appellants Apotex Inc., Apotex Corp., Actavis Elizabeth LLC, Accord Healthcare, Inc., Actavis LLC, Mylan Laboratories Limited and Fresenius Kabi USA, LLC in 18-1804. Service: 08/31/2018 by email. Appellant's reply brief is due 10/10/2018 [548778] [JB] [Entered: 09/11/2018 12:38 PM] (8) |
| Aug 20, 2018 | 65 | Amended Certificate of Interest for the Cross-Appellants Apotex Corp. and Apotex Inc.. Service: 08/20/2018 by email. [544154] [18-1804] [Andrew Alul] [Entered: 08/20/2018 04:20 PM] (2) |
| Aug 20, 2018 | 66 | Amended Certificate of Interest for the Cross-Appellants Actavis LLC and Actavis Elizabeth LLC. Service: 08/20/2018 by email. [544170] [18-1804] [Daryl Wiesen] [Entered: 08/20/2018 04:58 PM] (3) |
| Aug 20, 2018 | 67 | Amended Certificate of Interest for the Cross-Appellant Fresenius Kabi USA, LLC. Service: 08/20/2018 by email. [544172] [18-1804] [Daryl Wiesen] [Entered: 08/20/2018 05:00 PM] (3) |
| Aug 20, 2018 | 68 | TENDERED from Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Title: OPENING BRIEF. Service: 08/20/2018 by email. [544191] [18-1804] [Andrew Alul] [Entered: 08/20/2018 08:00 PM] (102) |
| Aug 20, 2018 | 69 | CORRECTED certificate of service for Cross-Appellants Apotex Corp. and Apotex Inc. for certificate of interest, Doc No. [65]. Service: 08/20/2018 by email. [544192] [18-1804] [Andrew Alul] [Entered: 08/20/2018 08:17 PM] (2) |
| Aug 20, 2018 | 70 | CORRECTED certificate of service for Cross-Appellants Apotex Corp. and Apotex Inc. for certificate of interest, Doc No. [65]. Service: 08/20/2018 by email. [544193] [18-1804] [Andrew Alul] [Entered: 08/20/2018 08:27 PM] (2) |
| Aug 20, 2018 | 71 | BRIEF FILED for Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited [68]. Number of Pages: 73. Service: 08/20/2018 by email. Appellees brief is due 10/1/2018. The paper copies of the brief should be received by the court on or before 09/04/2018. [545575] [JB] [Entered: 08/27/2018 01:22 PM] (102) |
| Aug 17, 2018 | 64 | Entry of appearance for Eric T. Romeo as of counsel for Cross-Appellants Actavis LLC, Fresenius Kabi USA, LLC and Actavis Elizabeth LLC. Service: 08/17/2018 by email. [543710] [18-1804] [Eric Romeo] [Entered: 08/17/2018 11:32 AM] (2) |
| Jul 27, 2018 | 63 | Certificate of Interest for the Cross-Appellant Mylan Laboratories Limited. Service: 07/27/2018 by email. [539038] [18-1804] [Matthew Reed] [Entered: 07/27/2018 12:38 PM] (4) |
| Jul 24, 2018 | 61 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellants' opening and response brief [60] filed by Cross-Appellants Apotex Inc., Apotex Corp., et al. The brief is due 08/20/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [538053] [MJL] [Entered: 07/24/2018 09:18 AM] (0) |
| Jul 24, 2018 | 62 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The information provided on the certificate of interest (COI) for Mylan Inc. attached to the motion [60] does not match the information on the COI originally filed for the party [33]. CORRECTION: Pursuant to FCR 47.4(c), as reminded by the court's note on 05/22/2018, please promptly file the most up-to-date COI as a separate docket entry. [538055] [MJL] [Entered: 07/24/2018 09:24 AM] (0) |
| Jul 23, 2018 | 60 | MOTION of Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited to extend the time to 08/20/2018 to file the August 6, 2018 deadline for Defendants - Cross-Appellants' Principal and Responsive Brief. [Consent: unopposed]. Service: 07/23/2018 by email. [537999] [18-1804] [Andrew Alul] [Entered: 07/23/2018 07:23 PM] (18) |
| Jun 28, 2018 | 59 | 6 paper copies of the Confidential Opening Brief [57] received from Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. [532501] [CJF] [Entered: 06/28/2018 11:43 AM] (0) |
| Jun 25, 2018 | 55 | TENDERED from Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Title: CONFIDENTIAL OPENING BRIEF Service: 06/25/2018 by email. [531849] [18-1804] [William Solander] [Entered: 06/25/2018 10:14 PM] (0) |
| Jun 25, 2018 | 56 | TENDERED from Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Title: OPENING BRIEF. Service: 06/25/2018 by email. [531850] [18-1804] [William Solander] [Entered: 06/25/2018 10:18 PM] (214) |
| Jun 25, 2018 | 57 | CONFIDENTIAL BRIEF FILED for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC [55]. Number of Pages: 49. Service: 06/25/2018 by email. The paper copies of the confidential brief should be received by the court on or before 07/03/2018. [532068] [CMP] [Entered: 06/26/2018 03:06 PM] (0) |
| Jun 25, 2018 | 58 | BRIEF FILED for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC [56]. Number of Pages: 49. Service: 06/25/2018 by email. The paper copies of the confidential brief should be received by the court on or before 07/03/2018. Cross-Appellants Accord Healthcare, Inc., Actavis Elizabeth LLC, Actavis LLC, Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited brief is due 08/06/2018. [532070] [CMP] [Entered: 06/26/2018 03:15 PM] (214) |
| Jun 22, 2018 | 54 | Entry of appearance for Dominick A. Conde as of counsel for Appellants Sanofi, Sanofi-Aventis U.S., LLC and Aventis Pharma S.A.. Service: 06/22/2018 by email. [531532] [18-1804] [Whitney Meier] [Entered: 06/22/2018 07:03 PM] (2) |
| May 29, 2018 | 52 | MOTION of Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC to extend the time to 06/25/2018 to file the Principal Brief. [Consent: unopposed]. Service: 05/29/2018 by email. [525015] [18-1804] [Whitney Meier] [Entered: 05/29/2018 12:41 PM] (8) |
| May 29, 2018 | 53 | **TEXT ONLY** ORDER granting motion to extend time to file brief [52] filed by Appellants Aventis Pharma S.A., Sanofi-Aventis U.S., LLC and Sanofi. Brief due 06/25/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [525018] [CFT] [Entered: 05/29/2018 12:48 PM] (0) |
| May 22, 2018 | 51 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [523451] [JB] [Entered: 05/22/2018 08:15 AM] (0) |
| May 9, 2018 | 50 | Entry of appearance for Kristina M. Hanson as of counsel for Cross-Appellant Mylan Laboratories Limited. Service: 05/09/2018 by email. [520552] [18-1804] [Kristina Hanson] [Entered: 05/09/2018 07:33 PM] (2) |
| May 3, 2018 | 49 | Official caption revised to reflect non-partipation of Appellees Breckenridge Pharmaceutical, Inc, BPI Labs, LLC and Belcher Pharmaceuticals, LLC. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [518675] [JB] [Entered: 05/03/2018 08:47 AM] (0) |
| May 2, 2018 | 48 | Letter from Appellees BPI Labs, LLC and Belcher Pharmaceuticals, LLC Request to remove BPI Labs, LLC and Belcher Pharmaceuticals, LLC from the docket.. Service: 05/02/2018 by email. [518593] [18-1804] [William Hare] [Entered: 05/02/2018 04:25 PM] (2) |
| May 1, 2018 | 45 | Official caption revised to reflect non-partipation of Appellees Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [517967] [JB] [Entered: 05/01/2018 09:59 AM] (0) |
| May 1, 2018 | 46 | OVERDUE NOTICE to counsel for Appellees BPI Labs, LLC, Belcher Pharmaceuticals, LLC and Breckenridge Pharmaceutical, Inc.: The record of this case indicates that no Entry of Appearance, Certificate of Interest or Docketing Statement has been filed for Appellees. Please file these documents promptly. Service as of this date by the Clerk of Court. [517971] [JB] [Entered: 05/01/2018 10:04 AM] (0) |
| May 1, 2018 | 47 | Letter from Appellee Breckenridge Pharmaceutical, Inc. Asking Court to remove Breckenridge and the Breckenridge District Court actions from docket.. Service: 05/01/2018 by email. [518273] [18-1804] [Kyle Musgrove] [Entered: 05/01/2018 05:37 PM] (3) |
| Apr 26, 2018 | 40 | NOTICE OF DEFICIENCY: The attorney entry of appearances [14], [13], docketing statement [16] filed by Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., have an incorrect party selection of "cross-appellant" and is not text-searchable. Also, the certificate of interest [15] filed by Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. in 18-1804 has more than one party designation being selected ("appellant" and "appellee") and document is not text searchable and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiencies. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [517011] [JB] [Entered: 04/26/2018 09:44 AM] (0) |
| Apr 26, 2018 | 41 | Entry of appearance for Frank D. Rodriguez as principal counsel for Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/26/2018 by email. [517195] [18-1804] [Frank Rodriguez] [Entered: 04/26/2018 06:11 PM] (3) |
| Apr 26, 2018 | 42 | Entry of appearance for James P. Barabas as of counsel for Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/26/2018 by email. [517196] [18-1804] [Frank Rodriguez] [Entered: 04/26/2018 06:12 PM] (3) |
| Apr 26, 2018 | 43 | Certificate of Interest for the Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/26/2018 by email. [517197] [18-1804] [Frank Rodriguez] [Entered: 04/26/2018 06:14 PM] (4) |
| Apr 26, 2018 | 44 | Docketing Statement for the Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/26/2018 by email. [517198] [18-1804] [Frank Rodriguez] [Entered: 04/26/2018 06:15 PM] (5) |
| Apr 25, 2018 | 9 | Entry of appearance for Imron T. Aly as principal counsel for Cross-Appellant Accord Healthcare, Inc.. Service: 04/25/2018 by email. [516784] [18-1804] [Helen Ji] [Entered: 04/25/2018 01:48 PM] (3) |
| Apr 25, 2018 | 10 | Entry of appearance for Helen H. Ji as of counsel for Cross-Appellant Accord Healthcare, Inc.. Service: 04/25/2018 by email. [516785] [18-1804] [Helen Ji] [Entered: 04/25/2018 01:50 PM] (3) |
| Apr 25, 2018 | 11 | Certificate of Interest for the Cross-Appellant Accord Healthcare, Inc.. Service: 04/25/2018 by email. [516787] [18-1804] [Helen Ji] [Entered: 04/25/2018 01:52 PM] (4) |
| Apr 25, 2018 | 12 | Docketing Statement for the Cross-Appellant Accord Healthcare, Inc.. Service: 04/25/2018 by email. [516790] [18-1804] [Helen Ji] [Entered: 04/25/2018 01:54 PM] (5) |
| Apr 25, 2018 | 13 | Entry of appearance for Frank D. Rodriguez as principal counsel for Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/25/2018 by email. [516842] [18-1804] [Frank Rodriguez] [Entered: 04/25/2018 03:38 PM] (0) |
| Apr 25, 2018 | 14 | Entry of appearance for James P. Barabas as of counsel for Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/25/2018 by email. [516846] [18-1804] [Frank Rodriguez] [Entered: 04/25/2018 03:40 PM] (0) |
| Apr 25, 2018 | 15 | Certificate of Interest for the Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/25/2018 by email. [516851] [18-1804] [Frank Rodriguez] [Entered: 04/25/2018 03:41 PM] (0) |
| Apr 25, 2018 | 16 | Docketing Statement for the Appellees Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 04/25/2018 by email. [516855] [18-1804] [Frank Rodriguez] [Entered: 04/25/2018 03:44 PM] (0) |
| Apr 25, 2018 | 17 | Entry of appearance for Daryl L. Wiesen as principal counsel for Cross-Appellants Fresenius Kabi USA, LLC, Actavis LLC and Actavis Elizabeth LLC. Service: 04/25/2018 by email. [516909] [18-1804] [Daryl Wiesen] [Entered: 04/25/2018 04:36 PM] (2) |
| Apr 25, 2018 | 18 | Certificate of Interest for the Cross-Appellants Actavis LLC and Actavis Elizabeth LLC. Service: 04/25/2018 by email. [516910] [18-1804] [Daryl Wiesen] [Entered: 04/25/2018 04:38 PM] (3) |
| Apr 25, 2018 | 19 | Certificate of Interest for the Cross-Appellant Fresenius Kabi USA, LLC. Service: 04/25/2018 by email. [516912] [18-1804] [Daryl Wiesen] [Entered: 04/25/2018 04:39 PM] (3) |
| Apr 25, 2018 | 20 | Docketing Statement for the Cross-Appellants Actavis LLC and Actavis Elizabeth LLC. Service: 04/25/2018 by email. [516915] [18-1804] [Daryl Wiesen] [Entered: 04/25/2018 04:42 PM] (3) |
| Apr 25, 2018 | 21 | Entry of appearance for William E. Solander as principal counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516916] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:42 PM] (2) |
| Apr 25, 2018 | 22 | Docketing Statement for the Cross-Appellant Fresenius Kabi USA, LLC. Service: 04/25/2018 by email. [516917] [18-1804] [Daryl Wiesen] [Entered: 04/25/2018 04:44 PM] (3) |
| Apr 25, 2018 | 23 | Entry of appearance for Daniel J. Minion as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516918] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:45 PM] (2) |
| Apr 25, 2018 | 24 | Entry of appearance for Jason A. Leonard as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516919] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:47 PM] (2) |
| Apr 25, 2018 | 25 | Entry of appearance for Emily L. Rapalino as of counsel for Cross-Appellants Fresenius Kabi USA, LLC, Actavis LLC and Actavis Elizabeth LLC. Service: 04/25/2018 by email. [516921] [18-1804] [Emily Rapalino] [Entered: 04/25/2018 04:48 PM] (2) |
| Apr 25, 2018 | 26 | Entry of appearance for Whitney L. Meier as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516922] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:48 PM] (2) |
| Apr 25, 2018 | 27 | Entry of appearance for Katherine E. Adams as of counsel for Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516924] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:50 PM] (2) |
| Apr 25, 2018 | 28 | Entry of appearance for Aviv A. Zalcenstein as of counsel for Cross-Appellants Fresenius Kabi USA, LLC, Actavis LLC and Actavis Elizabeth LLC. Service: 04/25/2018 by email. [516925] [18-1804] [Aviv Zalcenstein] [Entered: 04/25/2018 04:51 PM] (2) |
| Apr 25, 2018 | 29 | Certificate of Interest for the Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516927] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:52 PM] (3) |
| Apr 25, 2018 | 30 | Docketing Statement for the Appellants Aventis Pharma S.A., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/25/2018 by email. [516928] [18-1804] [Katherine Adams] [Entered: 04/25/2018 04:55 PM] (3) |
| Apr 25, 2018 | 31 | Entry of appearance for Matthew R. Reed as principal counsel for Cross-Appellant Mylan Laboratories Limited. Service: 04/25/2018 by email. [516950] [18-1804] [Matthew Reed] [Entered: 04/25/2018 07:12 PM] (2) |
| Apr 25, 2018 | 32 | Entry of appearance for Wendy L. Devine as of counsel for Cross-Appellant Mylan Laboratories Limited. Service: 04/25/2018 by email. [516953] [18-1804] [Matthew Reed] [Entered: 04/25/2018 07:16 PM] (2) |
| Apr 25, 2018 | 33 | Certificate of Interest for the Cross-Appellant Mylan Laboratories Limited. Service: 04/25/2018 by email. [516954] [18-1804] [Matthew Reed] [Entered: 04/25/2018 07:20 PM] (4) |
| Apr 25, 2018 | 34 | Docketing Statement for the Cross-Appellant Mylan Laboratories Limited. Service: 04/25/2018 by email. [516955] [18-1804] [Matthew Reed] [Entered: 04/25/2018 07:25 PM] (4) |
| Apr 25, 2018 | 35 | Entry of appearance for Joshua H. James as of counsel for Appellee Sandoz, Inc.. Service: 04/25/2018 by email. [516956] [18-1804] [Joshua James] [Entered: 04/25/2018 07:53 PM] (2) |
| Apr 25, 2018 | 36 | Entry of appearance for Mark H. Remus as of counsel for Appellee Sandoz, Inc.. Service: 04/25/2018 by email. [516957] [18-1804] [Joshua James] [Entered: 04/25/2018 07:57 PM] (2) |
| Apr 25, 2018 | 37 | Entry of appearance for Laura A. Lydigsen as principal counsel for Appellee Sandoz, Inc.. Service: 04/25/2018 by email. [516958] [18-1804] [Laura Lydigsen] [Entered: 04/25/2018 08:02 PM] (2) |
| Apr 25, 2018 | 38 | Docketing Statement for the Appellee Sandoz, Inc.. Service: 04/25/2018 by email. [516959] [18-1804] [Laura Lydigsen] [Entered: 04/25/2018 08:06 PM] (2) |
| Apr 25, 2018 | 39 | Certificate of Interest for the Appellee Sandoz, Inc.. Service: 04/25/2018 by email. [516961] [18-1804] [Laura Lydigsen] [Entered: 04/25/2018 08:08 PM] (3) |
| Apr 23, 2018 | 8 | Letter from Appellees Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. Requesting correction to caption. Service: 04/23/2018 by email. [516136] [18-1804] [Todd Werner] [Entered: 04/23/2018 03:20 PM] (1) |
| Apr 17, 2018 | 7 | Entry of appearance for Roshan P. Shrestha, Ph.D. as of counsel for Cross-Appellants Apotex Corp. and Apotex Inc.. Service: 04/17/2018 by email. [514251] [18-1804] [Roshan Shrestha] [Entered: 04/17/2018 03:40 PM] (4) |
| Apr 13, 2018 | 4 | Entry of appearance for Andrew M. Alul as principal counsel for Cross-Appellants Apotex Corp. and Apotex Inc.. Service: 04/13/2018 by email, US mail. [513277] [18-1804] [Andrew Alul] [Entered: 04/13/2018 01:10 PM] (5) |
| Apr 13, 2018 | 5 | Certificate of Interest for the Cross-Appellants Apotex Corp. and Apotex Inc.. Service: 04/13/2018 by email, US mail. [513280] [18-1804] [Andrew Alul] [Entered: 04/13/2018 01:16 PM] (6) |
| Apr 13, 2018 | 6 | Docketing Statement for the Cross-Appellants Apotex Corp. and Apotex Inc.. Service: 04/13/2018 by email, US mail. [513283] [18-1804] [Andrew Alul] [Entered: 04/13/2018 01:18 PM] (7) |
| Apr 12, 2018 | 3 | Official caption revised add Appellee (Sandoz, Inc). The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [512854] [JB] [Entered: 04/12/2018 12:46 PM] (0) |
| Apr 11, 2018 | 1 | Appeal docketed. Received: 04/05/2018. [512315]Entry of Appearance due 04/25/2018. Certificate of Interest is due on 04/25/2018. Docketing Statement due 04/25/2018. Appellant/Petitioner's brief is due 06/11/2018. [JB] [Entered: 04/11/2018 09:50 AM] (54) |
| Apr 11, 2018 | 2 | Note to file: The following cases are associated:18-1804 (Lead) with 18-1808 and 18-1809 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL 18-1804 ONLY. [512339] [18-1804, 18-1808, 18-1809] [JB] [Entered: 04/11/2018 10:34 AM] (0) |
